Opinion|Videos|June 3, 2024
Alzheimer’s Disease Pipeline
Key opinion leaders discuss the Alzheimer's disease pipeline and the numerous disease-modifying therapies under investigation.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Please provide an overview of robust Alzheimer’s pipeline and many disease modifying therapies under investigation.
- Discuss novel and emerging treatments that are most advanced in clinical studies or have promising data:
- Valiltramiprosate (ALZ-801,inhibits amyloid oligomer formation, oral)
- ALN-APP (RNAi therapeutic)
- Blarcamesine (sigma-1 and muscarinic receptors ligand)
Advertisement
Related to this article
Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.
Here's some of what is coming soon to NeurologyLive® this week.
The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
Joanna Wardlaw, MD, Professor of Applied Neuroimaging at the University of Edinburgh, discusses the evolving understanding of cerebral small vessel disease, emerging therapeutic approaches, and the makings behind a successful trial.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Sevasemten Misses Primary Endpoint in Pivotal Trial for Becker Muscular Dystrophy
2
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
3
PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS
4
Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162
5